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Reconstitution of telomerase activity in normal human cells leads
to elongation of telomeres and extended replicative life span
Homayoun Vaziri and Samuel Benchimol
Normal somatic cells have a finite life span [1] and lose
telomeric DNA, present at the ends of chromosomes,
each time they divide as a function of age in vivo or in
culture [2–4]. In contrast, many cancer cells and cell
lines established from tumours maintain their telomere
length by activation of an RNA–protein complex called
telomerase, an enzyme originally discovered in
Tetrahymena [5], that synthesizes telomeric repeats
[6–8]. These findings have led to the formation of the
‘telomere hypothesis’, which proposes that critical
shortening of telomeric DNA due to the end-replication
problem [9] is the signal for the initiation of cellular
senescence [10,11]. In yeast, the EST2 gene product, the
catalytic subunit of telomerase, is essential for telomere
maintenance in vivo [12–14]. The recent cloning of the
cDNA encoding the catalytic subunit of human
telomerase (hTERT) [15,16] makes it possible to test the
telomere hypothesis. In this study, we expressed hTERT
in normal human diploid fibroblasts, which lack
telomerase activity, to determine whether telomerase
activity could be reconstituted leading to extension of
replicative life span. Our results show that retroviral-
mediated expression of hTERT resulted in functional
telomerase activity in normal aging human cells.
Moreover, reconstitution of telomerase activity in vivo
led to an increase in the length of telomeric DNA and to
extension of cellular life span. These findings provide
direct evidence in support of the telomere hypothesis,
indicating that telomere length is one factor that can
determine the replicative life span of human cells.
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Results and discussion
The cDNA encoding hTERT was subcloned in the retro-
viral vector pBabe under the control of the promoter
present in the Moloney murine leukemia virus long
terminal repeat [17] in both sense (pBabest2) and anti-
sense (pBabest2-AS) orientation. The pBabe, pBabest2
and pBabest2-AS retroviruses were transfected into the
packaging cell line Phoenix-E and viral supernatants were
harvested. The normal human diploid fibroblast strain BJ,
previously transfected with the ecotropic virus receptor
gene [18], was infected with viral supernatants (multiplic-
ity of infection = 4) at approximately 75–79 population
doublings (PDs). These cells have approximately 10–15
PDs remaining before reaching senescence. Colonies
resistant to both G418 and hygromycin were selected,
isolated with cloning cylinders and expanded. BJ cells,
like other fibroblasts, do not normally have telomerase
activity [7], but they do express the RNA subunit (hTR) of
the telomerase complex [15]. We reasoned, therefore, that
BJ cells, which normally reach senescence after 87–90
PDs, represented a suitable recipient cell strain in which
to express hTERT, reconstitute telomerase activity, and
test for elongated telomeres and extended life span.
The pBabe-infected and pBabest2-AS-infected BJ cells
formed sparse and small colonies (Figure 1a,b). In contrast,
pBabest2-infected cells gave rise to many larger colonies
(Figure 1c). Ten drug-resistant colonies, each consisting of
approximately 250–350 cells, were isolated from each of
the infected cultures and expanded. In this secondary
plating assay, none of the 20 colonies derived from the
pBabe-infected or pBabest2-AS-infected cultures was
capable of dividing sufficiently to reach confluence even
after 14–20 days. These cells appeared to have reached
senescence after an estimated 87–90 PDs on the basis of
increased cell size, failure to divide and increased endoge-
nous β-galactosidase activity (Figure 2a,b) [19]. In contrast,
9 of 10 colonies obtained from the pBabest2-infected
Figure 1
Colony-forming ability of BJ cells infected with retroviruses encoding the
human telomerase catalytic subunit, hTERT, and controls. BJ cells
infected with (a) pBabest2-AS, (b) pBabe or (c) pBabest2 were
replated and selected in G418 and hygromycin. Cells were fixed and
stained with methylene blue to detect colonies. The total number of
colonies (containing ≥ 400 cells) in duplicate dishes was: pBabest2-AS,
14; pBabe, 31; and pBabest2, 244.
cultures reached confluence in the secondary plating assay.
To test for extended proliferative potential, single cells
were isolated by limiting dilution from the nine surviving
clones and grown in a tertiary plating assay. These cells
have now been in continuous culture and have reached a
minimum of 116 PDs (Table 1). The mean PD number for
the 10 pBabest2-infected clones was 28 PDs higher than
the 20 control clones (p < 10–5 by student’s t-test). No evi-
dence of β-galactosidase activity has been detected in
these dividing cultures (Figure 2c). To date, these cultures
show no sign of senescence and continue to divide. The
cells show no sign, so far, of aneuploidy and, like normal
fibroblasts, they arrest their growth in response to low
serum and undergo contact inhibition at high density 
(data not shown).
BJ cells infected with pBabest2 had reconstituted
telomerase activity as detected by the telomeric repeat
amplification protocol (TRAP) assay (Figure 3), or by the
conventional primer extension assay (data not shown),
whereas BJ cells infected with pBabe or pBabest2-AS had
no detectable activity (Figure 3). Reconstitution of telom-
erase activity has also been observed in other telomerase-
negative cells [20]. We refer to the pBabest2-infected
clones as TIELF cells (for telomerase-induced extended
life span human fibroblasts). TIELF cells continuously
expressed telomerase activity over time at PD 111, PD 117
and PD 123 (Figure 3). Extracts prepared from varying
numbers of cells indicated that the level of telomerase
activity in the TIELF cells was comparable to that of the
established adenovirus5-transformed human cell line 293
(Figure 3). Telomerase activity was sensitive to RNase and
heat treatment (Figure 3). 
Telomere length was measured using the terminal restric-
tion fragment (TRF) length assay as described previously
[4]. Genomic DNA was extracted from BJ cells and from
two independent TIELF clones at several PDs and the
mean TRF length was determined. As expected, control
BJ cells lose telomeric DNA with each PD at a rate of
–76 bp/PD (Figure 4a,b), similar to rates that we reported
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Figure 2
Endogenous β-galactosidase activity in BJ cells infected with retroviruses encoding the human telomerase catalytic subunit, hTERT, and controls.
Cells were infected with (a) pBabest2-AS (assessed at PD ~87), (b) pBabe (assessed at PD ~87) and (c) pBabest2 (assessed at PD 117).
Figure 3
Reconstitution of telomerase activity in BJ human diploid fibroblasts.
TRAP assays were performed as described previously [24]. Lane 1,
RNase-treated 293 cell extract serving as a negative control; lanes
2–5, 293 cell extracts corresponding to 105, 104, 103 and 102 cells,
respectively; lane 6, RNase-treated TIELF cell extract; lanes 7–9, cell
extracts derived from 103 TIELF cells at PD 111, PD 117 and PD 123,
respectively; lane 10, TIELF cell extract heated at 80°C for 3 min; lanes
11,12, cell extract corresponding to 100 and 50 TIELF cells,
respectively, at PD 123; lanes 13,14, cell extracts corresponding to
105 BJ cells infected with pBabest2-AS and pBabe, respectively.
Table 1
Extended life span of telomerase-positive clones.
Virus PD reached Number of clones Telomerase activity
pBabe 87–90* 10/10 —
pBabest2 >116 9/10 +
pBabest2-AS 87–90* 10/10 —
*PDs reached by pBabe and pBabest2-AS represent the maximum PD.
previously in these cells [21]. However, TIELF1 and
TIELF2, two clones derived from pBabest2-infected BJ
cells, acquired very long telomeres rapidly in the initial
expansion phase that continued to elongate with increas-
ing PD number; the approximate rates were +40 bp/PD
and +94 bp/PD in clones TIELF1 and TIELF2, respec-
tively (Figure 4a,b). An increase in the size and intensity
of the TRF signal from TIELF1 is evident from the
Southern blot shown in Figure 4a.
Our results provide direct evidence for the telomere
hypothesis. They show that forced expression of hTERT
cDNA in normal human cells results in telomerase
activity, elongation of telomere length and an extended
life span. Thus, normal human cells can bypass the
Hayflick limit and increase their replicative life span upon
expression of telomerase activity. It is notable that the
length of telomeric DNA was not merely maintained but
increased in TIELF cells. After submission of this manu-
script, similar results were reported by Bodnar et al. [22].
In contrast to their study, in which young/midlife cells
were used to extend life span, our study used older cells
that had completed 80% of their life span and, hence,
demonstrates that senescence can be prevented even in
old cells. Our results are reminiscent of studies with germ
cells, which, unlike somatic cells, express telomerase
activity, have long TRFs (~15 kb) and show a net increase
in the length of the telomeric DNA with age [23]. These
results suggest that expression of telomerase in normal
human cells might be associated with processes related to
de-differentiation and could lead to generation of cells
with the stem cell property of indefinite self renewal.
TIELF cells could replace genetically unstable, estab-
lished cell lines currently used in a wide variety of
applications. Ectopic expression of telomerase in normal
cells may be successfully used in gene therapy to increase
the life span of cells carrying the desired transgene.
Similar approaches can also be used for treatment of
aging-related diseases and cancer. 
Materials and methods
Cell culture
The neonatal human fibroblast cell strain (BJ) attained a maximum life
span of approximately 87–90 PDs under our conditions. Cells were
grown in α-minimal essential medium supplemented with 10% foetal
bovine serum (FBS). Older cells were grown in medium supplemented
with 15% FBS. Cells were split at a ratio of 1:4 or 1:8 at early passage
or at a ratio of 1:2 in later passages. Phosphate-buffered saline con-
tained no calcium or magnesium. Plating efficiency for BJ cells was
> 90%. PD number was calculated by the count/split method or as
PD = log(Nf/N0)/log2, where Nf is the final cell number and N0 is the
initial number of seeding cells.
Retroviral infection
The retroviral constructs were packaged using the highly efficient and
helper-free cell lines Phoenix-A and Phoenix-E (ATCC). Packaging
cells were transfected when approximately 80% confluent. Phoenix
cells were incubated in 25 µM chloroquine 5 min prior to transfection
with 10 µg retroviral plasmid DNA by the calcium phosphate tech-
nique. At 72 h post-transfection, the virus-containing medium was col-
lected and the virus titre determined using NIH3T3 cells. Titres of
2–4 × 106 transducing units per ml were obtained. BJ cells were
infected in the presence of polybrene (4 µg/ml) using viral super-
natants at a multiplicity of infection = 4. Throughout this work, the
transfection efficiencies were monitored by a cytomegalovirus–
enhanced green fluorescent protein (CMV–EGFP) construct. BJ cells
were incubated for 20 h at 32°C in virus-containing medium. Fresh
media was added and the cells were incubated for a further 24 h in
virus-free media prior to trypsinization and plating in media supple-
mented with G418 (400 µg/ml) and hygromycin (20–50 µg/ml). Drug-
resistant colonies were isolated with cloning rings approximately 2–3
weeks later. Throughout this work, BJ cells carrying pM5-Eco (the
ecotropic receptor gene) were used.
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Figure 4
Analysis of TRFs in BJ and BJ-derived TIELF
cells. Genomic DNA, purified by DNAzol
(BRL), was digested with HinfI and RsaI,
quantitated in triplicate by fluorometry and
1 µg DNA per lane was resolved on a 0.5%
agarose gel. A γ[32P]-end-labelled (C3TA2)3
probe was used to detect and measure the
length of telomeric DNA as previously
described [4]. (a) Lanes 1–3, DNA size
markers; lanes 4,5, blank; lane 6, young BJ
cells at PD 29; lane 7, BJ cells at PD 51; lane
8, old BJ cells at PD 87; lanes 9–12, TIELF1
cells with increasing PDs as indicated; lanes
13,14, BJ cells infected with control (C)
pBabest2-AS and pBabe, respectively, at PD
~50–55. (b) Quantitative analysis of telomeric
DNA in normal BJ cells and the TIELF cells.
Normal BJ cells lost telomeric DNA at a rate
of –76 bp/PD, r = –0.98. Two TIELF cell
clones increased their telomere length at a
rate of +40 bp/PD, r = –0.96 and +94 bp/PD,
r = –0.98.
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